Irish medtech startup Nua Surgical has raised €6.5 million in a Series A round. It was led by EQT Life Sciences via its EQT Health Economics strategy, with participation from Texas Medical Center Venture Fund, Kidron Capital, and existing supporters such as Enterprise Ireland. IT also saw business veterans from Ireland and the US.
This investment follows similar rounds, including UK-based Silveray and Swedish startup Amferia.
The new investment will support Nua Surgical’s next phase of development and the early commercialisation of its product – SteriCISION. This includes expanding the team, establishing manufacturing in Ireland, and meeting the regulatory requirements to gain FDA clearance.
In addition to the investment, EQT’s Anne Portwich and Kidron Capital’s Anula Jayasuriya joined the company’s board, underscoring its commitment to diverse leadership.
Tackles safety and efficiency in C-section surgeries
C-sections are the most common major surgical procedure globally, with over 30 million performed each year. These procedures come with risks such as wound trauma, bleeding complications, and infections. Traditional surgical tools are not tailored for the unique dynamics of C-sections, often resulting in suboptimal surgical outcomes.
This is where Nua Surgical comes into the picture addressing critical challenges in maternal healthcare, improving the safety and efficiency of C-section surgeries.
How was the idea born?
Nua Surgical was founded in 2019 by Barry McCann, Marie-Therese Maher, and Padraig Maher after spinning out of the BioInnovate Ireland programme at the University of Galway. Identifying an unmet need, the founders focused on designing an ergonomic, single-use sterile device to provide safer and more effective surgical solutions.
Its SteriCISION C-Section Retractor emerged from deep research into the challenges of maternal surgery.
What does SteriCISION do?
SteriCISION is a surgical retractor designed for C-section procedures. Unlike generic retractors, it provides fast, adjustable, and secure retraction tailored to the unique demands of Caesarean surgery. By improving access and visualisation of the uterus, the device enables safer delivery, precise tissue repair, and quick identification of bleeding.
As a single-use sterile device, SteriCISION minimises infection risks and streamlines surgical workflows, addressing critical challenges that traditional tools fail to meet. Its ergonomic design ensures ease of use for clinicians, ultimately enhancing outcomes for both mothers and babies while reducing complications and healthcare costs.
What’s next for Nua Surgical?
As the company progresses toward commercialisation, the SteriCISION device stands to redefine maternal healthcare globally, setting new standards for safety and efficiency in C-section surgeries. This latest milestone solidifies Nua Surgical’s position as a leader in maternal health innovation, showcasing the potential of Irish ingenuity to address global medical challenges.
Barry McCann, CEO of Nua Surgical, commented, “Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercialising SteriCISION.”
“Nua Surgical’s SteriCISION C-Section Retractor has the potential to significantly enhance outcomes for mothers undergoing C-Section procedures,” said Anne Portwich, Partner at EQT. “We are excited to support the company’s journey towards market entry. This innovative device shows promise in potentially improving the quality of care and reducing healthcare costs, making it a perfect fit for our EQT Health Economics strategy.”
The post Irish medtech Nua Surgical closes €6.5M for safer, smarter C-section solutions appeared first on Tech Funding News.